Healthcare company Avrio Health LP said on Thursday that the Betadine Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or PVP-I) killed 99.9% of the COVID-19 virus within 15 seconds in an in vitro (laboratory) study.
The company added that the Betadine Gargle containing 0.5% PVP-I demonstrated virucidal activity against SARS-CoV-2 and four surrogate coronaviruses in separate in vitro studies conducted by Utah State University, Institute for Antiviral Research, BluTest Laboratories, Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia as well as the Duke-NUS Medical School in Singapore.
According to the company, Betadine Antiseptic Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be swallowed, is an oral antiseptic with use for the temporary relief of occasional sore throat. Betadine Antiseptic Sore Throat Gargle will be available in retail stores in late August 2020. All products should be used only as directed on the label.
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
GMJ Technologies names new CEO
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Antengene granted IND approval in China for ATG-201 in autoimmune disease
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Argo Biopharma to present updated BW-20805 Phase II results at EAACI 2026 Congress
Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
OriCell's GPC3 CAR-T Phase II hepatocellular carcinoma trial receives Chinese regulatory clearance
Owkin to build AI agents as part of K Pro collaboration with Sanofi
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline